# DropGenie

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dropgenie

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.dropgenie.com
- Total disclosed funding: $8.2M
- Latest round: Seed (Oct 26, 2026)
- Investors on record: 13

## About

DropGenie is a technology company focused on delivering innovative digital solutions that enhance user experience and optimize operational efficiency across various sectors through cloud-based applications.Founded in 2018 in Massachusetts, US, DropGenie specializes in providing digital solutions tailored for businesses. Alison Hirukawa and Philippe Vo are among the co-founders, with Hirukawa also serving as the CEO. In June 2026, DropGenie, Inc. raised USD 3.22 million seed funding led by Skeleton Key, with participation from Merck Global Health Innovation Fund, Khosla Ventures, Felicis Ventures, Quebec Consortium for Drug Discovery, Real Ventures, and AQC Capital. DropGenie specializes in innovative digital solutions designed to enhance user experience and optimize operational efficiency within various sectors. Its core offerings include a comprehensive suite of cloud-based applications that facilitate seamless data management and analytics for businesses, improving customer engagement, streamlining supply chain processes, and providing insightful business intelligence. The company's products target small to medium-sized enterprises (SMEs) across North America, Europe, and parts of Asia, serving diverse clients from retail to service sectors.DropGenie generates revenue through a subscription-based model, offering clients tiered access to its digital applications. The company partners with various industry players for bundled offerings, utilizing both direct-to-consumer sales and B2B transactions. Its pricing plans are designed to accommodate different business sizes, ensuring flexibility for users while maximizing the company's revenue potential, with flagship services known for their robust functionality. DropGenie plans to launch new products designed to enhance functionality for its users, with specific release dates yet to be announced. The company will use the June 2026 funding to support commercialization by scaling manufacturing, building commercial operations, and accelerating customer adoption of its product.

## Funding rounds

- Seed, Oct 26, 2026, $5M — BDC Thrive Venture Fund, Skeleton Key, Anges Québec, Merck Global Health Innovation Fund, Real Ventures, CQDM, BDC Capital's Thrive Fund
- Seed, Jun 16, 2026, $3.2M — Khosla Ventures, Merck Global Health Innovation Fund, Felicis Ventures, Real Ventures, Quebec Consortium for Drug Discovery, AQC Capital, Skeleton Key
- Seed, Jan 25, 2022 — SOSV
- Seed, Nov 12, 2021 — SOSV
- Seed, Jul 27, 2018 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Seed
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed
- Real Ventures — Seed
- Quebec Consortium for Drug Discovery — Seed
- AQC Capital (https://capitalatlas.ai/funds/aqc-capital) — Seed
- Skeleton Key (https://capitalatlas.ai/funds/skeleton-key) — Seed
- BDC Thrive Venture Fund — Seed
- Anges Québec — Seed
- CQDM — Seed
- BDC Capital's Thrive Fund — Seed